PubMed · 10996624
Antitumor vaccination using peptide based vaccines.
Abstract
Cytotoxic T Lymphocytes (CTLs) recognize Major Histocompatibility Complex (MHC) class I in complex with peptides. Peptides derived from Tumor Associated Antigens (TAAs) are therefore targets for tumor rejection. A number of TAAs were identified in the last decade from human and murine tumors. Here we summarize the methods for TAA and peptide identification, the nature of TAA peptides and the making of antitumor vaccines.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
L Eisenbach, E Bar-Haim, K El-Shami. 2000-09-15. Antitumor vaccination using peptide based vaccines.. https://doi.org/10.1016/s0165-2478(00)00245-5
Cite the original work for its findings. Save a collection to share your selection of sources.